Table 3.
Distributions of Clinical and Screening Factors by Multivitamin Use at Baseline
| Recency of Multivitamin Use at Baseline | Cumulative Years of Multivitamin Use at Baseline | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Never n=17,719 | Former n=2,821 | Current n=14,347 | None n=17,719 | <5 years n=5,502 | ≥5 years n=11,666 | |
|
| ||||||
| Length of follow-up time on trial, mean yrs | 5.2 | 5.2 | 5.2 | 5.2 | 5.2 | 5.2 |
| Number of PSA per year of follow-up, mean (SD) | 0.9 (0.3) | 0.9 (0.3) | 1.0 (0.3) | 0.9 (0.3) | 1.0 (0.3) | 1.0 (0.3) |
| Number of DRE per year of follow-up, mean (SD) | 0.8 (0.3) | 0.8 (0.3) | 0.8 (0.3) | 0.8 (0.3) | 0.8 (0.3) | 0.8 (0.3) |
| Median PSA at first on-study biopsy 1 | 3.8 | 3.7 | 3.6 | 3.8 | 3.5 | 3.7 |
| N (%) with on-study biopsy | 2473 (14.0%) | 390 (13.8%) | 2150 (15.0%) | 2473 (14.0%) | 777 (14.1%) | 1763 (15.1%) |
| N with PSA>4 or abnormal DRE at any point in study and no biopsy | 1475 (8.3%) | 246 (8.7%) | 1233 (8.6%) | 1475 (8.3%) | 451 (8.2%) | 1028 (8.8%) |
| N (%) with negative biopsy prior to SELECT | 1563 (8.8%) | 236 (8.4%) | 1608 (11.2%) | 1563 (8.8%) | 482 (8.8%) | 1362 (11.7%) |
| HR (95% CI) | HR (95% CI) | |||||
|
|
||||||
| Time to first biopsy on-study 2 | Ref | 0.99 (0.94–1.05) | 1.10 (1.06–1.13) | Ref | 1.02 (0.98–1.06) | 1.11 (1.07–1.14) |
1
Most recent recorded PSA at the time of first recorded biopsy, for both cases and non-cases. For cases with no recorded biopsy, diagnosis date is used.
2
Hazard ratios adjusted for age, family history of prostate cancer, PSA and DRE (longitudinal)